Mass General Brigham
Health Plan

Kynmobi (apomorphine)
Effective 11/01/2020

Plan	☐ MassHealth UPPL ☒ Commercial/Exchange	**Program Type**	☒ Prior Authorization ☒ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	**Medical and Specialty Medications** All Plans | Phone: 877-519-1908 | Fax: 855-540-3693		
	Non-Specialty Medications All Plans | Phone: 800-711-4555 | Fax: 844-403-1029		
Exceptions	N/A		

Overview
Apomorphine is a non-ergoline dopamine agonist. Kynmobi is a sublingual film indicated for acute, intermittent treatment of "off" episodes in patients with Parkinson's disease.

Coverage Guidelines
Authorization may be granted for members new to the plan who are currently receiving treatment with Kynmobi excluding when the product is obtained as samples or via manufacturer's patient assistance programs.
OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. The member has a diagnosis of acute, intermittent "off" episodes in patients with Parkinson disease.
2. The member is ≥ 18 years old
3. Provider specialty is neurology or medication is being prescribed in consultation with a neurologist

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member's condition.

Limitations

1. Initial approvals and reauthorizations will be approved for 12 months.
2. The following quantity limits apply:

Kynmobi	150 films per 30 days

References

1. Kynmobi (apomorphine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; May 2020.
2. Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Mov Disord 2016; 31:1366
3. Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 2020; 19:135

Review History
09/16/2020 – Reviewed and Created Sept P&T Mtg. Effective 11/01/20.
09/22/2021 – Reviewed P&T; reworded overview; references updated; no clinical updates
11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.